Periprocedural Anticoagulation - DOAC and Warfarin Interruption and Bridging

Key Points

• Periprocedural management is based on both thrombotic risk and procedure bleeding risk.
• Most DOAC interruptions do not require heparin bridging.
• Most atrial-fibrillation patients on warfarin should not receive routine bridging.
• Dabigatran interruption depends strongly on renal function.
• Neuraxial procedures use specialty-specific anticoagulant intervals.
• Write the exact last dose and restart plan.
• Postoperative restart requires secure hemostasis, not just elapsed time.
• Aspirin and P2Y12 antiplatelet decisions should be handled separately from anticoagulant management.

Algorithm

1. Identify anticoagulant, indication, dose, last dose, renal function, and thrombosis history.
2. Classify the procedure as minimal, low/moderate, or high bleeding risk and identify neuraxial involvement.
3. Decide whether interruption is necessary at all.
4. For DOAC interruption, calculate the drug-specific hold from renal function and procedure risk without routine bridging.
5. For warfarin, plan sufficient hold for INR recovery and determine whether rare high-risk bridging is justified.
6. Document the last dose, procedure date, and any perioperative prophylaxis.
7. Restart when procedural hemostasis is secure, usually later after high-bleeding-risk surgery.
8. Provide the patient and procedural team the same written medication plan.

Clinical Synopsis & Reasoning

Begin with four questions: why is the patient anticoagulated, what drug and dose are they taking, how well do they clear the drug, and how much bleeding would the planned procedure cause if anticoagulant effect remained. Thrombotic risk differs markedly among a patient with remote provoked VTE, nonvalvular atrial fibrillation, a recent VTE, and a patient with a high-risk mechanical valve. Procedure risk ranges from minor dental or dermatologic interventions to major surgery and neuraxial procedures.

Direct oral anticoagulants have rapid offset and onset. Routine LMWH bridging during DOAC interruption adds bleeding without replacing a long pharmacologic gap because the gap is already short. CHEST guidance generally recommends holding apixaban, edoxaban, and rivaroxaban roughly 1 to 2 days before elective procedures that require interruption, with longer interruption for dabigatran when renal clearance is reduced and longer holds for high-bleeding-risk procedures. Exact timing should use procedure and renal-function tables.

Warfarin usually requires several days of interruption for a procedure that needs normal hemostasis. Routine bridging is discouraged for most atrial fibrillation and many other indications because trials show increased bleeding without sufficient thrombotic benefit. Bridging is reserved for selected very-high-risk circumstances after individualized assessment. Aspirin management is separate and depends on cardiovascular indication and procedure type.

Treatment Strategy & Disposition

Create a written anticoagulation calendar rather than giving vague instructions to "stop a few days before." For DOACs, specify the final preprocedure dose, the procedure date, and restart time. In normal renal function, many low- or moderate-bleeding-risk procedures use a short 1-day interruption, while high-risk surgery often uses about 2 days; dabigatran requires greater adjustment for creatinine clearance. Neuraxial anesthesia follows specialty-specific ASRA intervals that are often longer than general-surgery intervals.

For warfarin, stop early enough for the INR to fall to an acceptable procedural level, commonly around 5 days for many procedures. Do not bridge routinely. If the patient has an exceptionally high thromboembolic risk, discuss bridging with the managing specialist using the valve, VTE timing, stroke history, and other factors. When bridging is chosen, therapeutic LMWH or UFH timing must minimize residual anticoagulation at incision.

Postoperative restart depends on hemostasis. CHEST suggests restarting DOAC about 24 hours after low- or moderate-bleeding-risk surgery and 48 to 72 hours after high-risk surgery when hemostasis is secure. Warfarin can often resume earlier because therapeutic effect is delayed. Never restart solely because a clock interval elapsed if active bleeding or surgical concern remains. Coordinate with the proceduralist, anticoagulation service, and anesthesia team.

Epidemiology / Risk Factors

• DOAC use has made short planned interruptions increasingly common.
• Bridging historically was overused in atrial fibrillation and increased bleeding.
• Renal impairment is especially important for dabigatran clearance.
• Medication communication failures are a major preventable source of perioperative bleeding and thrombosis.

Investigations

When to Consider Bridging

Pharmacology

Prognosis / Complications

• Most elective procedures can be completed safely with a standardized interruption plan.
• Unnecessary bridging increases postoperative bleeding.
• Restarting too early after high-risk surgery can cause major hemorrhage, while prolonged unexplained interruption increases thrombosis risk.
• Written standardized pathways reduce medication errors.

Patient Education / Counseling

• Give the patient exact dates and times for the last and next anticoagulant doses.
• Tell the patient not to add LMWH or resume early unless instructed.
• Clarify whether aspirin or other antiplatelet drugs follow a separate plan.
• Ask the patient to report unexpected preoperative bleeding or a missed/extra dose.
• After surgery, report wound bleeding, melena, hematuria, chest pain, unilateral leg swelling, or neurologic symptoms urgently.

Notes

CHEST 2022 moved practice further away from routine bridging. The important conceptual shift is that "high concern about thrombosis" does not automatically mean LMWH is beneficial. Bridging itself has a measurable bleeding cost and should be reserved for circumstances in which the untreated interruption risk is truly exceptional.

Exact DOAC hold intervals belong in a drug-by-drug institutional table because renal function, dose, procedure risk, and neuraxial techniques matter. A medical reference should teach the decision framework while directing clinicians to the current procedural protocol for exact timing.

References

1. CHEST Guideline: Perioperative Management of Antithrombotic Therapy — Link
2. CHEST Perioperative Antithrombotic Therapy Guideline — Link